The global antibody-drug conjugates market size is experiencing a significant CAGR of around 16% during the forecast period 2022 to 2028. The rising prevalence of cancer around the world is a primary factor driving the market growth. As per the latest information shared by the National Institute of Health, about 1,898,160 new cancer cases were found in 2021, and 608,570 deaths were recorded in the United States. According to WHO, cancer is a leading cause of death accounting for around 10 million deaths in 2020. The changing lifestyle, unhealthy diets, smoking, and alcohol consumption are some of the major causes of rising cancer. Furthermore, the increasing research & development and the growing investment by some major players are further anticipated to fuel the market growth over the forecast period.
Market Drivers:
Increasing Prevalence of Cancer: The rising incidence of cancer globally is a significant driving factor for the ADCs market. ADCs are primarily used in cancer treatment and offer targeted therapy by delivering cytotoxic drugs directly to cancer cells. With the increasing burden of cancer and the need for more effective treatment options, the demand for ADCs has been growing.
Advancements in Antibody Technology: Advances in antibody technology have enabled the development of more specific and potent ADCs. The availability of a wide range of monoclonal antibodies with different target specificities has expanded the potential applications of ADCs. Innovations in antibody engineering, such as antibody humanization, bispecific antibodies, and antibody fragment technologies, have further contributed to the growth of the ADCs market.
Favorable Regulatory Environment: The regulatory environment has a significant impact on the development and commercialization of ADCs. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established guidelines and accelerated approval pathways for ADCs in certain indications. The favorable regulatory environment facilitates the development and commercialization of ADCs, driving market growth.
Targeted and Personalized Medicine Approach: ADCs offer a targeted and personalized approach to cancer treatment. They can selectively deliver cytotoxic drugs to cancer cells while sparing healthy cells, reducing systemic toxicity and side effects associated with traditional chemotherapy. The shift towards targeted therapies and personalized medicine drives the demand for ADCs in the treatment of various types of cancer.
Potential for Enhanced Efficacy and Safety: ADCs have the potential to improve treatment outcomes by enhancing the efficacy and safety of cancer therapies. By delivering cytotoxic drugs directly to cancer cells, ADCs can increase the concentration of the drug at the tumor site while minimizing exposure to healthy tissues. This targeted approach improves the therapeutic index and reduces side effects, making ADCs an attractive treatment option.
Growing Investment in Research and Development: The pharmaceutical and biotechnology industries have been investing heavily in research and development (R&D) activities related to ADCs. These investments are driven by the potential of ADCs to address unmet medical needs in cancer treatment. The ongoing R&D efforts focus on optimizing ADC design, exploring new targets, and developing novel linker technologies, leading to the development of more efficacious ADCs.
Collaborations and Partnerships: Collaborations and partnerships between pharmaceutical companies, biotechnology firms, and research institutions have played a significant role in advancing ADC research and development. These collaborations leverage the expertise and resources of different stakeholders, accelerating the development and commercialization of ADCs. Collaborative efforts contribute to the growth of the ADCs market by fostering innovation and expanding product pipelines.
Increasing Healthcare Expenditure: The increasing healthcare expenditure, particularly in emerging economies, has a positive impact on the adoption of ADCs. As healthcare budgets expand, there is a greater willingness to invest in innovative and targeted therapies, such as ADCs, to improve patient outcomes. The growing affordability and accessibility of healthcare services contribute to the demand for ADCs.
Expansion of Indications and Therapeutic Areas: Initially, ADCs were primarily developed for hematological malignancies. However, the scope of ADCs has expanded to include solid tumors and various therapeutic areas. The development of ADCs for new indications, such as breast cancer, lung cancer, and ovarian cancer, has broadened their market potential and increased their adoption in different clinical settings.
Market Snapshot:
| Benchmark Year | 2022 | ||
| Market Size | lock | ||
| Market Growth (CAGR) | ~ 16% (2023-2030) | ||
| Largest Market Share | North America | ||
| Analysis Period | 2020-2030 | ||
| Market Players | Seagen, Inc., AstraZeneca, Takeda Pharmaceutical Company Limited, Pfizer, Inc., and F. Hoffmann-La Roche Ltd. |
Market Insights:
The global antibody drug conjugates market is bifurcated into product, technology, application, end-user, and geography. On the basis of application, the market is further segmented into blood cancer, breast cancer, ovary cancer, lung cancer, and others. The breast cancer segment dominated the global market in 2021 and expected to maintain its dominance over the forecast period. the high prevalence of breast cancer globally is a major factor to drive the segment growth. According to the latest information shared by WHO, in 2020, 2.26 million new cases were diagnosed with breast cancer and 685,000 deaths were recorded globally.
On the basis of technology, the market is segmented into cleavable linker, non- cleavable linker, and linkerless. The cleavable linker segment dominated the global antibody-drug conjugates market in 2021 and expected to grow at the same trend over the forecast period. The higher preference for the technology in cancer treatment due to its more effective outcome is a major factor to drive the segment growth. On the flip side, the linkerless segment is accounted to register the highest growth rate over the forecast period. The increasing prevalence of hairy cell leukemia is a primary factor to fuel the segment growth over the forecast period.
To know more about the report, request sample papers
The antibody drug conjugates comprehensive study analyzes industry trends, market size, competitive analysis, and market forecast – 2022 to 2028. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.
The antibody drug conjugates market research report presents the analysis of each segment from 2019 to 2028 considering 2020 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2027.
Historical & Forecast Period
- 2019-20 – Historical Year
- 2021 – Base Year
- 2022-2028 – Forecast Period
Market Segmentation:
By Product Type:
- Adcetris
- Kadcyla
- Others
By Technology:
- Cleavable Linker
- Non-cleavable Linker
- Linkerless
By Application:
- Blood Cancer
- Breast Cancer
- Ovary Cancer
- Lung Cancer
- Skin Cancer
- Brain Tumor
- Others
By End-User:
- Hospitals and Speciality Cancer Centers
- Biotechnology and Pharmaceutical Companies
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Regional Analysis:
Geographically, North America dominated the global antibody-drug conjugates market in 2021 and estimated to grow at the same trend over the forecast period. The increasing rate of cancer prevalence and the availability of well-structured healthcare infrastructure are some major factors to drive the market growth in the region. Furthermore, the technological advancement and the presence of some major players are further anticipated to fuel the market growth in North America. On the other hand, the Asia Pacific is expected to register the fastest growth rate over the forecast period.
Competitive Assessment:
Some of the major market players operating in the global antibody-drug conjugates market are Seagen, Inc., AstraZeneca, Takeda Pharmaceutical Company Limited, Pfizer, Inc., and F. Hoffmann-La Roche Ltd. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.
Key Companies:
- Seagen, Inc.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Hoffmann-La Roche Ltd.
- Daiichi Sankyo Company Limited
- Gilead Sciences, Inc.
- Astellas Pharma, Inc.
- GlaxoSmithKline plc
- ADC Therapeutics SA
Key Questions Answered by Antibody Drug Conjugates Market Report
- Global antibody-drug conjugates market forecasts from 2022-2028
- Regional market forecasts from 2022-2028 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
- Country-level forecasts from 2022-2028 covering 15 major countries from the regions as mentioned above
- Antibody drug conjugates submarket forecasts from 2022-2028 covering the market by product type, by technology, by application, by end-user, and geography
- Various industry models such as SWOT analysis, Value Chain Analysis about the market
- Analysis of the key factors driving and restraining the growth of the global, regional, and country-level antibody drug conjugates markets from 2022-2028
- Competitive Landscape and market positioning of top 10 players operating in the market
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.4. Assumptions
2. Executive Summary
2.1. Global Antibody Drug Conjugates Market Portraiture
2.2. Global Antibody Drug Conjugates Market, by Product Type, 2021 (USD Mn)
2.3. Global Antibody Drug Conjugates Market, by Technology, 2021 (USD Mn)
2.4. Global Antibody Drug Conjugates Market, by Application, 2021 (USD Mn)
2.5. Global Antibody Drug Conjugates Market, by End-User, 2021 (USD Mn)
2.6. Global Antibody Drug Conjugates Market, by Geography, 2021 (USD Mn)
3. Global Antibody Drug Conjugates Market Analysis
3.1. Antibody Drug Conjugates Market Overview
3.2. Market Inclination Insights
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Challenges
3.3.3. Opportunities
3.4. Attractive Investment Proposition
3.5. Competitive Analysis
3.6. Porter’s Five Force Analysis
3.6.1. Bargaining Power of Suppliers
3.6.2. Bargaining Power of Buyers
3.6.3. Threat of New Entrants
3.6.4. Threat of Substitutes
3.6.5. Degree of Competition
3.7. COVID-19 Impact Analysis
4. Global Antibody Drug Conjugates Market By Product Type, 2019 – 2028 (USD Mn)
4.1. Overview
4.2. Adcetris
4.3. Kadcyla
4.4. Others
5. Global Antibody Drug Conjugates Market By Technology, 2019 – 2028 (USD Mn)
5.1. Overview
5.2. Cleavable Linker
5.3. Non-cleavable Linker
5.4. Linkerless
6. Global Antibody Drug Conjugates Market By Application, 2019 – 2028 (USD Mn)
6.1. Overview
6.2. Blood Cancer
6.3. Breast Cancer
6.4. Ovary Cancer
6.5. Lung Cancer
6.6. Skin Cancer
6.7. Brain Tumor
6.8. Others
7. Global Antibody Drug Conjugates Market By End-User, 2019 – 2028 (USD Mn)
7.1. Overview
7.2. Hospitals and Speciality Cancer Centers
7.3. Biotechnology and Pharmaceutical Companies
7.4. Others
8. North America Antibody Drug Conjugates Market Analysis and Forecast, 2019 – 2028 (USD Mn)
8.1. Overview
8.2. North America Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
8.3. North America Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
8.4. North America Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
8.5. North America Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
8.6. North America Antibody Drug Conjugates Market by Country, (2019-2028 USD Mn)
8.6.1. U.S.
8.6.1.1. U.S. Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
8.6.1.2. U.S. Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
8.6.1.3. U.S. Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
8.6.1.4. U.S. Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
8.6.2. Canada
8.6.2.1. Canada Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
8.6.2.2. Canada Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
8.6.2.3. Canada Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
8.6.2.4. Canada Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
9. Europe Antibody Drug Conjugates Market Analysis and Forecast, 2019 – 2028 (USD Mn)
9.1. Overview
9.2. Europe Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
9.3. Europe Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
9.4. Europe Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
9.5. Europe Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
9.6. Europe Antibody Drug Conjugates Market by Country, (2019-2028 USD Mn)
9.6.1. Germany
9.6.1.1. Germany Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
9.6.1.2. Germany Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
9.6.1.3. Germany Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
9.6.1.4. Germany Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
9.6.2. U.K.
9.6.2.1. U.K. Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
9.6.2.2. U.K. Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
9.6.2.3. U.K. Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
9.6.2.4. U.K. Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
9.6.3. France
9.6.3.1. France Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
9.6.3.2. France Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
9.6.3.3. France Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
9.6.3.4. France Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
9.6.4. Italy
9.6.4.1. Italy Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
9.6.4.2. Italy Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
9.6.4.3. Italy Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
9.6.4.4. Italy Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
9.6.5. Rest of Europe
9.6.5.1. Rest of Europe Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
9.6.5.2. Rest of Europe Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
9.6.5.3. Rest of Europe Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
9.6.5.4. Rest of Europe Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
10. Asia Pacific Antibody Drug Conjugates Market Analysis and Forecast, 2019 – 2028 (USD Mn)
10.1. Overview
10.2. Asia Pacific Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
10.3. Asia Pacific Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
10.4. Asia Pacific Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
10.5. Asia Pacific Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
10.6. Asia Pacific Antibody Drug Conjugates Market by Country, (2019-2028 USD Mn)
10.6.1. China
10.6.1.1. China Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
10.6.1.2. China Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
10.6.1.3. China Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
10.6.1.4. China Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
10.6.2. Japan
10.6.2.1. Japan Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
10.6.2.2. Japan Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
10.6.2.3. Japan Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
10.6.2.4. Japan Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
10.6.3. India
10.6.3.1. India Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
10.6.3.2. India Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
10.6.3.3. India Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
10.6.3.4. India Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
10.6.4. Rest of Asia Pacific
10.6.4.1. Rest of Asia Pacific Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
10.6.4.2. Rest of Asia Pacific Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
10.6.4.3. Rest of Asia Pacific Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
10.6.4.4. Rest of Asia Pacific Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
11. Latin America (LATAM) Antibody Drug Conjugates Market Analysis and Forecast, 2019 – 2028 (USD Mn)
11.1. Overview
11.2. Latin America Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
11.3. Latin America Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
11.4. Latin America Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
11.5. Latin America Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
11.6. Latin America Antibody Drug Conjugates Market by Country, (2019-2028 USD Mn)
11.6.1. Brazil
11.6.1.1. Brazil Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
11.6.1.2. Brazil Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
11.6.1.3. Brazil Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
11.6.1.4. Brazil Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
11.6.2. Mexico
11.6.2.1. Mexico Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
11.6.2.2. Mexico Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
11.6.2.3. Mexico Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
11.6.2.4. Mexico Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
11.6.3. Rest of Latin America
11.6.3.1. Rest of Latin America Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
11.6.3.2. Rest of Latin America Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
11.6.3.3. Rest of Latin America Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
11.6.3.4. Rest of Latin America Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
12. Middle East and Africa Antibody Drug Conjugates Market Analysis and Forecast, 2019 – 2028 (USD Mn)
12.1. Overview
12.2. MEA Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
12.3. MEA Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
12.4. MEA Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
12.5. MEA Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
12.6. Middle East and Africa Antibody Drug Conjugates Market, by Country, (2019-2028 USD Mn)
12.6.1. GCC
12.6.1.1. GCC Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
12.6.1.2. GCC Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
12.6.1.3. GCC Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
12.6.1.4. GCC Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
12.6.2. South Africa
12.6.2.1. South Africa Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
12.6.2.2. South Africa Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
12.6.2.3. South Africa Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
12.6.2.4. South Africa Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
12.6.3. Rest of MEA
12.6.3.1. Rest of MEA Antibody Drug Conjugates Market by Product Type, (2019-2028 USD Mn)
12.6.3.2. Rest of MEA Antibody Drug Conjugates Market by Technology, (2019-2028 USD Mn)
12.6.3.3. Rest of MEA Antibody Drug Conjugates Market by Application, (2019-2028 USD Mn)
12.6.3.4. Rest of MEA Antibody Drug Conjugates Market by End-User, (2019-2028 USD Mn)
13. Company Profiles
13.1. Seagen, Inc.
13.1.1. Business Description
13.1.2. Financial Health and Budget Allocation
13.1.3. Product Positions/Portfolio
13.1.4. Recent Development
13.1.5. SWOT Analysis
13.2. AstraZeneca
13.2.1. Business Description
13.2.2. Financial Health and Budget Allocation
13.2.3. Product Positions/Portfolio
13.2.4. Recent Development
13.2.5. SWOT Analysis
13.3. Takeda Pharmaceutical Company Limited
13.3.1. Business Description
13.3.2. Financial Health and Budget Allocation
13.3.3. Product Positions/Portfolio
13.3.4. Recent Development
13.3.5. SWOT Analysis
13.4. Pfizer, Inc.
13.4.1. Business Description
13.4.2. Financial Health and Budget Allocation
13.4.3. Product Positions/Portfolio
13.4.4. Recent Development
13.4.5. SWOT Analysis
13.5. F. Hoffmann-La Roche Ltd.
13.5.1. Business Description
13.5.2. Financial Health and Budget Allocation
13.5.3. Product Positions/Portfolio
13.5.4. Recent Development
13.5.5. SWOT Analysis
13.6. Daiichi Sankyo Company Limited
13.6.1. Business Description
13.6.2. Financial Health and Budget Allocation
13.6.3. Product Positions/Portfolio
13.6.4. Recent Development
13.6.5. SWOT Analysis
13.7. Gilead Sciences, Inc.
13.7.1. Business Description
13.7.2. Financial Health and Budget Allocation
13.7.3. Product Positions/Portfolio
13.7.4. Recent Development
13.7.5. SWOT Analysis
13.8. Astellas Pharma, Inc.
13.8.1. Business Description
13.8.2. Financial Health and Budget Allocation
13.8.3. Product Positions/Portfolio
13.8.4. Recent Development
13.8.5. SWOT Analysis
13.9. GlaxoSmithKline plc
13.9.1. Business Description
13.9.2. Financial Health and Budget Allocation
13.9.3. Product Positions/Portfolio
13.9.4. Recent Development
13.9.5. SWOT Analysis
13.10. ADC Therapeutics SA
13.10.1. Business Description
13.10.2. Financial Health and Budget Allocation
13.10.3. Product Positions/Portfolio
13.10.4. Recent Development
13.10.5. SWOT Analysis
$ 5200/- Multi User License
We understand that every business has unique requirements. This report can be customized based on:
- Deep regional & country-level market intelligence
- Application-specific and end-use industry segmentation
- Competitive landscape & strategic benchmarking
- Go-to-market and expansion strategy insights
- Custom data cuts aligned to your business goals
- Structured Primary Research Framework
- On-Demand Industry Expert Interviews Available
- Dedicated Analyst Support
- Custom Data On Request
- Post-Purchase Strategy Consultation
- Complimentary 30-min Analyst Session
- 30% of Our Clients Are Returning Enterprise Buyers
Our Clients
